Open AccessSurvival following screening and preemptive antifungal therapy for subclinical cryptococcal disease in advanced HIV infection
Author(s) -
Tariro Makadzange,
Admire Hlupeni,
Rhoderick Machekano,
Kathryn Boyd,
Takudzwa J. Mtisi,
Primrose Nyamayaro,
Christine Ross,
Snighdha Vallabhaneni,
Shirish Balachandra,
Prosper Chonzi,
Chiratidzo E. Ndhlovu
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002971
Subject(s) - medicine , fluconazole , cryptococcosis , subclinical infection , amphotericin b , tuberculosis , cryptococcus gattii , prospective cohort study , immunology , gastroenterology , surgery , pathology , antifungal , dermatology
Our study's primary objective was to compare 1-year survival rates between serum cryptococcal antigen (sCrAg)-positive and sCrAg-negative HIV-positive individuals with CD4+ cell counts less than 100 cells/μl without symptoms of meningitis in Zimbabwe.